See more : Hasti Finance Limited (HASTIFIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Mesoblast Limited (MESO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesoblast Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Banco do Estado do Rio Grande do Sul S.A. (BRSR5.SA) Income Statement Analysis – Financial Results
- Arcontech Group plc (ARC.L) Income Statement Analysis – Financial Results
- Base Resources Limited (BSRUF) Income Statement Analysis – Financial Results
- 8I Holdings Limited (8IH.AX) Income Statement Analysis – Financial Results
- Prestige Consumer Healthcare Inc. (PBH) Income Statement Analysis – Financial Results
Mesoblast Limited (MESO)
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M | 17.34M | 2.41M | 42.55M | 23.75M | 25.98M | 28.79M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Cost of Revenue | 41.07M | 54.92M | 63.57M | 85.73M | 81.50M | 75.17M | 5.51M | 12.07M | 29.76M | 23.78M | 25.43M | 21.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M | -58.45M | 11.83M | -9.65M | 12.79M | -35.00K | 546.00K | 7.52M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Gross Profit Ratio | 100.00% | -632.20% | -522.58% | -1,049.83% | -153.44% | -349.55% | 68.24% | -400.21% | 30.05% | -0.15% | 2.10% | 26.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.35M | 27.19M | 32.82M | 53.01M | 56.19M | 59.82M | 65.93M | 58.91M | 50.01M | 77.59M | 55.31M | 43.11M | 36.94M | 15.31M | 7.57M | 7.15M | 6.21M | 4.58M | 5.36M | 491.77K |
| General & Administrative | 23.63M | 25.37M | 27.21M | 30.87M | 25.61M | 21.63M | 21.91M | 23.01M | 22.50M | 36.17M | 26.56M | 30.73M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Selling & Marketing | 0.00 | 27.73M | 30.76M | 32.72M | 25.31M | 15.36M | 5.51M | 12.07M | 29.76M | 29.21M | 27.61M | 20.95M | 22.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 53.11M | 57.97M | 63.59M | 50.92M | 36.98M | 27.42M | 35.07M | 52.26M | 65.38M | 54.17M | 51.68M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Other Expenses | 0.00 | 0.00 | 30.76M | 32.65M | 25.23M | 15.48M | -1.31M | 10.53M | 25.92M | 122.00K | 16.49M | 15.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.98M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Cost & Expenses | 90.05M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Interest Income | 0.00 | 831.00K | 3.00K | 22.00K | 542.00K | 719.00K | 366.00K | 468.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 739.79K | 704.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 19.44M | 16.91M | 10.71M | 13.33M | 11.33M | 1.83M | 0.00 | 9.31M | 10.53M | 4.33M | 0.00 | 289.00 | 14.91K | 0.00 | 0.00 | 0.00 | 542.00 | 110.09K | 107.12K |
| Depreciation & Amortization | 1.90M | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M | 2.65M | 3.06M | 2.19M | 1.96M | 1.12M | 772.00K | 378.59K | 178.88K | 153.29K | 119.83K | 156.76K | 62.52K | 43.58K | 18.98K |
| EBITDA | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M | -78.06M | -74.69M | -87.16M | -28.07M | -90.19M | -67.01M | -59.31M | -48.34M | 92.44M | -10.97M | -9.31M | -7.78M | -6.95M | -8.14M | -1.34M |
| EBITDA Ratio | -1,064.44% | -866.94% | -749.91% | -1,443.17% | -234.50% | -485.36% | -430.71% | -3,729.48% | -65.98% | -487.90% | -257.92% | -206.02% | -68.78% | 76.44% | -199,515.44% | -1,045.14% | -855.44% | -515.99% | -288.65% | -267.31% |
| Operating Income | -84.15M | -69.29M | -80.57M | -109.10M | -74.87M | -80.20M | -77.34M | -90.04M | -55.89M | -113.39M | -72.38M | -60.08M | -48.72M | 93.76M | -10.39M | -9.43M | -7.94M | -7.01M | -6.28M | -986.54K |
| Operating Income Ratio | -982.24% | -923.73% | -789.09% | -1,463.20% | -232.84% | -479.62% | -445.99% | -3,733.08% | -131.35% | -477.48% | -278.58% | -208.71% | -127.28% | 77.54% | -188,851.78% | -1,058.60% | -872.67% | -417.64% | -222.70% | -196.18% |
| Total Other Income/Expenses | -4.00M | -12.81M | -10.48M | 9.47M | -12.48M | -18.34M | 9.24M | -173.00K | -34.93M | -4.45M | -3.15M | 0.00 | -289.00 | -1.52M | -4.39M | -2.86M | -2.12M | -1.71M | -2.01M | -483.83K |
| Income Before Tax | -88.15M | -82.10M | -91.59M | -99.63M | -87.36M | -98.75M | -65.98M | -90.22M | -90.82M | -119.37M | -80.95M | -60.08M | -48.72M | 92.24M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Income Before Tax Ratio | -1,493.51% | -1,094.53% | -896.93% | -1,336.24% | -271.66% | -590.56% | -380.47% | -3,740.26% | -213.46% | -502.64% | -311.60% | -208.71% | -127.28% | 76.28% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| Income Tax Expense | 191.00K | -212.00K | -239.00K | -819.00K | -9.42M | -8.96M | -30.69M | -13.40M | -86.69M | 6.10M | 5.00K | 1.59M | 22.42M | 1.63M | -739.79K | 0.00 | 0.00 | -1.71M | -1.79M | -269.59K |
| Net Income | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.82M | -4.13M | -119.37M | -80.96M | -61.66M | -71.15M | 90.61M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Net Income Ratio | -1,490.27% | -1,091.71% | -894.59% | -1,325.25% | -242.38% | -537.01% | -203.51% | -3,184.70% | -9.70% | -502.64% | -311.62% | -214.21% | -185.86% | 74.93% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| EPS | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.41 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.39 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 986.70M | 739.04M | 648.78M | 605.07M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
| Weighted Avg Shares Out (Dil) | 986.70M | 739.04M | 648.90M | 605.09M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
5 Stocks to Ride the Santa Claus Rally
Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in the seven-day period.
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the...
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for...
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023.
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk...
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric...
Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO ) Q4 2023 Results Conference Call August 30, 2023 6:30 PM ET Company Participants Dr. Silviu Itescu - Chief Executive Officer Dr. Eric Rose - Chief Medical Officer Andrew Chaponnel - Interim Chief Financial Officer Dr. Philip...
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors are advised to contact Robert S.
Source: https://incomestatements.info
Category: Stock Reports